DrugPatentWatch Database Preview
Details for Patent: 6,517,847
» See Plans and Pricing
Which drugs does patent 6,517,847 protect, and when does it expire?
Patent 6,517,847 protects ALTRENO, ARAZLO, BRYHALI, and DUOBRII, and is included in four NDAs.
This patent has thirty-four patent family members in twenty-two countries.
Summary for Patent: 6,517,847
| Title: | Topical gel delivery system |
| Abstract: | A composition is provided that has a viscosity of less than about 15,000 cP and a pH of about 3.0 to 9.0 for treating a skin disorder in a human subject. The composition is a lotion that consists essentially of (a) a therapeutically-effective amount of at least one compound useful for treating such disorder, (b) a pharmaceutically-acceptable, lightly cross-linked polyacrylic acid polymer compatible with the compound, (c) a pharmaceutically acceptable base to adjust pH, (d) up to about 25% ww of at least one water miscible solvent, (e) optionally a preservative, (f) water, and (g) an oil phase component and suitable surfactant. The composition is useful for treating an inflammatory skin disorder, acne, or rosacea. |
| Inventor(s): | Dow; Gordon J. (Santa Rosa, CA), Lathrop; Robert W. (Novato, CA), Dow; Debra A. (Petaluma, CA) |
| Assignee: | Dow Pharmaceutical Sciences (Petaluma, CA) |
| Application Number: | 10/096,516 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Recent additions to Drugs Protected by US Patent 6,517,847
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | ARAZLO | tazarotene | LOTION | 211882 | Dec 18, 2019 | RX | Yes | Start Trial | Y | Start Trial | U-2368 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 6,517,847
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dow Pharm | ALTRENO | tretinoin | LOTION;TOPICAL | 209353-001 | Aug 23, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER | Start Trial | |||
| Bausch | ARAZLO | tazarotene | LOTION;TOPICAL | 211882-001 | Dec 18, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER | Start Trial | |||
| Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,517,847
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 030093 | Start Trial | |||
| Austria | 429922 | Start Trial | |||
| Australia | 2001279002 | Start Trial | |||
| Australia | 7900201 | Start Trial | |||
| Brazil | 0113247 | Start Trial | |||
| Canada | 2417646 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
